HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Government Backs Vitamin D COVID Benefits With Supplement Handout

Executive Summary

By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.

You may also be interested in...



Vitamin D Supplements And COVID-19: Still No Evidence, No Harm In Doing It Anyway

Two new RCTs cast further doubt on the preventative effects of vitamin D supplementation with regards to COVID-19 infection. Nevertheless, an editorial in the British Medical Journal, where the studies were published, leaves open positive effects for those suffering from vitamin D deficiency, and recommends a daily supplement of up to 2000IU just in case.

UK Government Seeks Ways To Boost Uptake Of Vitamin D Supplements

While the UK government recommends all UK adults take vitamin D supplements for at least part of the year, uptake is poor. In an effort to address this, the Office for Health Improvement & Disparities wants to identify ways of increasing access to, and availability of, vitamin D supplements.

French Experts Call For Mass Vitamin D Supplementation To Fight COVID-19

With around half the French population vitamin D deficient, a group of medical experts say mass supplementation is a low cost and low risk intervention which could save lives and curb the spread of COVID-19.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150759

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel